TCP Venture Capital

TCP Venture Capital is a Baltimore, Maryland-based early-stage, technology-focused venture capital firm founded in 2012 that partners with entrepreneurs to build great businesses. The firm invests in early-stage companies across technology, education, healthcare, cybersecurity, analytics and advanced-materials sectors, concentrating on unique technology applications and explicitly excluding franchises, brick-and-mortar operations and online retail. Its flagship Propel Baltimore Fund makes investments in early-stage technology companies based in, or willing to relocate to, Baltimore, with an explicit mission to address the city's shortage of early-stage capital, encourage entrepreneurial activity and create high-paying jobs. TCP was founded by Christopher College and Stuart Sutley and is managed by a team with over 140 years of combined experience, and it is willing to lead rounds. Managing Partner Christopher College is a seasoned venture investor who has closed more than 100 deals totaling over $2.5 billion and previously headed the Private Finance Group at Stifel Nicolaus; Partner Stuart Sutley is a University of Virginia graduate, former US Marine Corps infantry officer and healthcare-company founder. Across roughly 30 to 35 investments the portfolio has produced eight acquisitions, including ZeroFox, RedOwl, Protenus and Rocket Doctor (acquired by Canada's Treatment AI), with other holdings such as WellDoc, EcoMap, Indicio, Link Labs, Traitify, Yet Analytics, Pixelligent Technologies, emocha and Minnowtech. Its most recent tracked investment was a Series A in Baltimore-based Infinity Bio in June 2025. By anchoring its flagship fund in Baltimore, TCP backs regional technology founders while addressing a local capital gap.